Printer Friendly

Utility of Immunohistochemistry in the Pancreatobiliary Tract.

Pancreatic epithelial neoplasms can be simply classified into solid and cystic neoplasms based on their gross appearances, as illustrated in Figure 1. Pancreatic ductal adenocarcinoma (DADC) and its variants, such as colloid carcinoma and medullary carcinoma, account for approximately 85% of neoplasms, followed by intraductal papillary mucinous neoplasms (IPMNs) at 3% to 5%, and pancreatic neuroendocrine tumors (P-NETs) at 3% to 4%. (1,2) Mucinous cystic neoplasm (MCNs), acinar cell carcinomas (ACCs), solid pseudopapillary tumors (SPT), and serous cystadenomas (SCA) are uncommon neoplasms of the pancreas. (1,2) Accurate diagnosis for each entity is crucial for making therapeutic decisions and predicting a prognostic outcome. Numerous immunohistochemical (IHC) markers to improve diagnostic accuracy have been described in the literature. (1-49) The selected immunomarkers for differentiating these neoplasms are summarized in Table 1. The applications and pitfalls of important markers will be reviewed throughout this article.


Distinguishing pancreatic DADC from nonneoplastic pancreatic tissues/diseases, including chronic pancreatitis and autoimmune pancreatitis, can be challenging, especially in small biopsies and fine-needle aspiration biopsy (FNAB) specimens. Numerous immunomarkers have been reported to be useful in solving that problem. Those markers include von Hippel-Lindau tumor suppressor (pVHL), placental S100 (S100P), mammary serine protease inhibitor (maspin), insulin-like growth factor II messenger RNA binding protein-3 (IMP3), mesothelin, prostate stem cell antigen (PSCA), annexin A8, fascin, claudin 4, claudin 18, p53, SMAD family member 4 (DPC4/SMAD4), carcinoembryonic antigen (CEA), cytokeratin (CK) 17, CK19, mucin (MUC) 1, MUC2, MUC5AC, cancer antigen 19-9 (CA19-9), and EPCAM. (1-49) More recently, 3 additional biomarkers (annexin A10, plectin 1, and aldo-keto reductase family 1, member B10 [AKR1B10]) have been reported as useful markers to differentiate pancreatic DADCs from benign/ reactive pancreatic ducts. (50-52) Specifically, annexin A10, a calcium and phospholipid-binding protein expressed in normal gastric mucosa, was found to be positive in 78% (57 of 73) of primary pancreatic DADCs and 83% (19 of 23) of metastatic pancreatic DADCs, 46% (154 of 337) of primary gastric ADCs and 47% (36 of 77) of metastatic gastric adenocarcinomas (ADCs), and only 2% of metastatic ADCs from other organs. (50) Plectin 1 was reported to be positive in 100% of primary and metastatic pancreatic DADCs and 60% of pancreatic intraepithelial neoplasia (PanIN) 3 cases, but it was negative in all chronic pancreatitis and normal pancreatic tissues. (51) AKR1B10 was found to be expressed in 70% (35 of 50) of pancreatic DADCs and most PanINs. (52) We do not have experience with these 3 newly described immunomarkers. Additional studies are needed to further validate the clinical utilities of those 3 markers.

In our previous study, (48) we investigated the utility of 26 IHC markers (CAM 5.2, CK7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, caudal type homeobox 2 [CDX2], pVHL, S100P, IMP3, maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA, EPCAM, CEA, and CA19-9) in 60 cases of pancreatic DADC on tissue microarray and routine tissue sections. We also performed immunohistochemical stains for maspin, S100P, IMP3, and pVHL on cell blocks of 67 pancreatic FNAB specimens, including 44 cases of pancreatic DADC and 27 benign/reactive cases. The results demonstrated that (1) more than 90% of pancreatic DADCs were positive for maspin, S100P, and IMP3; (2) nearly all pancreatic DADCs were negative for pVHL, whereas nonneoplastic ducts and acini were positive for pVHL in all cases; (3) normal/reactive pancreatic ducts were frequently positive for CK7, CK19, MUC1, MUC6, CA19-9, EPCAM, PSCA, mesothelin, annexin A8, claudin 4, and claudin 18; (4) normal pancreatic ducts were usually negative for IMP3, maspin, S100P, CK17, MUC2, MUC4, and MUC5AC; (5) 60% of pancreatic DADCs were negative for DPC4/SMAD4, and 50% of cases were strongly positive for p53; (6) loss of pVHL expression and S100P overexpression were observed in all PanINs, regardless of grade; and (7) strong background staining was frequently seen with fascin, PSCA, and annexin A8.48 Markers like tumor-associated glycoprotein 72 (TAG 72/B72.3), EPCAM, and epithelial cell adhesion molecule (Ber-EP4) were usually positive in pancreatic DADCs, but they were frequently positive or weakly positive in normal or reactive ducts as well. In contrast, monoclonal CEA (mCEA) was strongly positive in most pancreatic DADCs, and the adjacent stroma also showed positivity because of the leaking of mCEA into the adjacent tissue. Normal/reactive ducts tended to be negative or only weakly positive for mCEA. (48)

Based on that study and review of the literature, (48) we concluded that pVHL, maspin, S100P, IMP3, CK17, MUC5AC, and DPC4/SMAD4 were the best diagnostic panel of immunomarkers for confirming the diagnosis of pancreatic DADCs in both surgical and FNAB specimens. In an autoimmune pancreatitis, the infiltrating plasma cells were predominately positive for immunoglobulin G4 (IgG4). An immunostain for IgG4 may be helpful in diagnosing a difficult case. (53-55) The presence of abundant IgG4-positive plasma cells does not, however, preclude the diagnosis of pancreatic DADC because, in a small subset of pancreatic DADC cases, the cancer-adjacent tissue may show features of autoimmune pancreatitis. The useful immunomarkers for the distinction between a pancreatic DADC and reactive ducts are summarized in Table 2. Additional discussion of pVHL, S100P, maspin, IMP3, MUC5AC, and CK17 will follow in the section below. An example of pancreatic DADC showing expression of pVHL, maspin, pVHL/maspin double stain, S100P, IMP3, MU C5AC, and DPC4/SMAD4 is illustrated in Figure 2, A through H.

VHL (von Hippel-Lindau) is a tumor suppressor gene. Inactivation of the VHL gene on band 3p25-26 by mutation, deletion, or hypermethylation is a frequent event in both hereditary and sporadic clear cell renal cell carcinomas (RCCs). (56,57) Genetic alteration of the VHL gene appears to be a crucial step in the initiation and progression of clear cell RCC. Our previous study demonstrated pVHL was expressed in most renal cell neoplasms, including clear cell RCCs, papillary RCCs, chromophobe RCCs, and oncocytomas (47) and in more than 90% of metastatic RCCs. In addition, 90% of clear cell carcinomas of the ovary and uterus were positive for pVHL. (47) In contrast, many tumors from various organs, including carcinomas of the lung, pancreas, gastrointestinal tract, adrenal gland, prostate, and bladder, were negative for pVHL. (47) Interestingly, normal/reactive pancreatic ducts and acinar cells were positive for pVHL. Expression of pVHL has been also tested in ADCs of the gallbladder, extrahepatic bile ducts and intrahepatic bile ducts. (58-61) The results demonstrated (1) only 6% of gallbladder ADCs were positive for pVHL, (60) (2) 7.5% of extrahepatic bile duct ADCs were positive for pVHL, (58) and (3) in contrast, 71% of intrahepatic cholangiocarcinomas (ICCs) were positive for pVHL. (61) Therefore, pVHL may have a role in the distinction of pancreatic DADC, gallbladder adenocarcinoma (ADC), and extrahepatic ADC from ICC.

S100P belongs to the family of S100 calcium binding proteins. It is a 95 amino acid protein first purified from the human placenta. The level of S100P expression has been found to increase during the progression from PanIN to invasive ADC. (42-44,46) Expression of S100P has been reported in more than 90% of pancreatic DADCs, gallbladder ADCs, and extrahepatic ADCs. (46,48,58-60) In contrast, only 27%% of ICCs were positive for S100P. (61) Similar observations have also been reported by Aishima et al, (62) who found positive nuclear S100P staining in 8 of 69 (12%) of the peripheral-type ICCs, in contrast to 28 of 41 (68%) of the perihilar cholangiocarcinomas. Tsai et al (63) reported a higher frequency of S100P expression in peripheral ICCs (53%), but in most of their positive cases, the staining was heterogeneous with mixed nuclear, cytoplasmic and extracellular patterns. It is unclear how many of those cases showed nuclear S100P expression. In addition, one-half of their positive cases exhibited only focal staining. (63) Overexpression of S100P was also frequently observed in IPMNs and MCNs but not in ACCs, P-NETs, and SCAs. (64,65) Reactive ducts may show cytoplasmic staining for S100P. As a rule, only nuclear positivity or both nuclear and cytoplasmic positivity was regarded as positive staining for S100P.

Maspin, also known as serpin B5, is a tumor suppressor gene expressed in some human epithelial cells. Maspin overexpression can be seen in carcinomas from various organs including most ADCs of the pancreas and gallbladder and in ICCs; * however, maspin overexpression was also reported in nontumorous gallbladder epithelium in patients with cholelithiasis and intestinal metaplasia. (66,67) Therefore, maspin alone cannot be used as a reliable diagnostic marker to differentiate benign from malignant gallbladder glandular lesions. Normal and reactive pancreatic ducts are usually negative for maspin. (48)

IMP3 is an oncofetal RNA-binding protein, also known as K homology domain containing protein overexpressed in cancer, IGF2BP3, and L523S. Immunohistochemical expression of IMP3 has been reported in various cancers, including ADCs of the pancreas, endocervix, and neuroendocrine carcinomas of the lung. (20-23,48,58-60) Expression of IMP3 was demonstrated in 37 of 38 (97%), (20) 99 of 112 (88.4%), (22) and 54 of 60 (90%) of the ADCs of the pancreas. (48) Similar findings of IMP3 expression in FNABs of the pancreas were reported. (23) Expression of IMP3 was reported in 81%, 64%, and 90% of ADCs of the gallbladder, extrahepatic bile ducts, and intrahepatic bile ducts, respectively. (58-61)

MUC5AC is a high-molecular-weight glycoprotein of the mucin family, which has been shown to serve an important role in pancreatic tumorigenesis. (68,69) Overexpression of MUC5AC has been reported in 60% to 100% of pancreatic DADCs in several studies. (10,48,70,71) Similarly, a high frequency of MUC5AC expression has been reported in cholangio carcinoma (10,72-75) and in gallbladder ADC. (60,72,76) In the studies in which ICCs and extrahepatic cholangiocarcinomas were separately evaluated, it was apparent that extrahepatic cholangiocarcinomas more frequently expressed MUC5AC than ICCs. (70,72) Another interesting observation was that peripheral-type ICCs showed MUC5AC expression less commonly than hilar cholangiocarcinomas. In the study by Guedjet al, (77) 32 of 52 hilar cholangiocarcinomas (62%) showed positivity for MUC5AC, in contrast to 13 of 59 (22%) peripheral ICCs. Similarly, Aishima et al (78) reported positive MUC5AC staining in 69% to 72% of hilar tumors but only 25% to 27% of peripheral ICCs (2 different anti-MUC5AC antibodies were used in that study). The study from our group showed a similar finding of a higher frequency of MUC5AC expression in pancreatic DADCs (67%) than in ICCs (12%). (61)

CK17 is a low-molecular-weight keratin that is normally expressed in myoepithelial and basal cells and subsets of hair shaft epithelia. (10) A few studies have demonstrated it to be of value in the distinction between pancreaticobiliary and nonpancreaticobiliary ADCs. (7,10,79,80) Our data showed CK17 expression in 60% of pancreatic DADCs but only 12% of ICCs. (48,61) Our findings of CK17 expression in ICCs seem to be different from those reported by Chu et al, (10) who detected CK17 expression in 17 of 24 ICCs (71%). However, it is unclear whether hilar or perihilar cholangiocarcinomas were included in that study. To support our findings, Sarbia et al (79) showed positive CK17 staining in 10 of 17 ADCs (59%) of the extrahepatic bile ducts, a frequency similar to ours. (48,61)

Two variants of pancreatic DADC should be mentioned here. One is colloid carcinoma, and the other is medullary carcinoma. Colloid carcinoma is usually positive for CDX2 and MUC2, but negative for MUC1, which is the opposite to the IHC profile of a conventional pancreatic DADC. (1,2,81) Identification of colloid carcinoma is important because it carries a much better prognosis than does a conventional pancreatic DADC. Medullary carcinoma of the pancreas is rare and frequently demonstrates loss of DNA mismatch repair proteins, especially MutL homolog 1 (MLH1) and postmeiotic segregation increased 2 (PMS2). (1,2,82-84) Our unpublished data demonstrated that both colloid carcinoma and medullary carcinoma show a similar IHC profile for the expression of pVHL, S100P, maspin, and IMP3 when compared with pancreatic DADCs.


In addition to the distinction between pancreatic DADCs and chronic pancreatitis/reactive ducts, another frequently encountered diagnostic problem is to differentiate P-NET from its mimics, such as ACC, SPT and rarely pancreatoblastoma (PB). The frequently used immunomarkers in making that differential diagnosis are summarized in Table 3. The applications and pitfalls for some of the markers are discussed in detail below.

Acinar Cell Carcinoma

Acinar cell carcinoma of the pancreas is a very rare, nonductal carcinoma, which accounts for about 1% of pancreatic neoplasms in adults and approximately 15% in pediatric patients. (1,2) The differential diagnosis from pancreatic DADC is relatively straightforward based on its morphologic features and the IHC profile. The diagnostic challenge is to differentiate ACC from a neuroendocrine neoplasm and an SPT. Perhaps the most difficult diagnostic problem is how to distinguish ACC from PB; sometimes, it is nearly impossible because of the significant overlapping of both morphologic and IHC features, especially in a smallcore biopsy or an FNAB specimen. The classic IHC profile of an ACC is outlined in Table 4.

Our experience and that of others showed CK7 is frequently negative or only focally positive in ACCs, which provides a useful clue for differentiating an ACC from a pancreatic DADC, which is nearly always diffusely positive for CK7. A histochemical stain of periodic acid-Schiff diastase is usually positive in ACC. Trypsin is usually positive but may give strong background staining. Up to 25% of ACCs may show both nuclear and cytoplasmic positivity for [beta]-catenin, (85,86) which can create a problem in the distinction of an ACC from an SPT or a PB. Chromogranin was usually negative or showed only scattered positivity in endocrine cells. When more than 25% of tumor cells are positive for endocrine markers, the tumor is regarded as a mixed acinar and endocrine carcinoma. Based on our experience, other markers, including mesothelin, pVHL, S100P, and maspin, are usually negative in ACCs.

Several recently described immunomarkers have been reported to be useful in confirming a diagnosis of ACC. The antibody against COOH-terminal BCL10 was shown to be positive in normal acinar cells and in 82% (14 of 17) of ACCs by Hosoda et al (87) and 85% (40 of 47) of ACCs by La Rosa et al. (88) BCL10 expression was not seen in P-NETs, pancreatic DADCs, SPTs, SCAs, MCNs, or IPMNs. (87) Two of 4 adenosquamous carcinomas (50%) were positive for BCL10. (87) Glypican-3, an established immunomarker for hepatocellular carcinoma and yolk sac tumor, was positive in 58% (7 of 12) of ACCs but negative in pancreatic DADCs and P-NETs. (89) Carboxyl ester lipase has been found to be another sensitive marker positive in 91% (29 of 32) of ACCs. (88)

Pancreatic Neuroendocrine Tumor

Pancreatic neuroendocrine tumors are uncommon, accounting for approximately 3% of all pancreatic neoplasms. (1,2) Diagnosis of P-NET can be challenging because of the limited experience a pathologist may have with it and the variety of morphologic variants, including spindle cell, oncocytic cell, rhabdoid cell, pleomorphic cell, lipid-rich, and clear cell. The current World Health Organization classification of P-NETs was based on counting mitoses or mindbomb homolog 1 (MlB1/Ki-67) proliferative index. (1) Pancreatic neuroendocrine tumors are divided into (1) PNET grade 1 (0-1 mitosis/10 high-power fields or <2% MIB1 index), (2) P-NET grade 2 (2-20 mitoses/10 highpower fields or 3%-20% MIB1 index), and (3) pancreatic neuroendocrine carcinoma (large cell neuroendocrine carcinoma or small cell carcinoma; >20 mitoses/10 high-power fields or >20% MIB1 index). Neuroendocrine features can be confirmed by immunoreactivity to synaptophysin, chromogranin, and CD56. Our experience and that of others showed nearly 100% of P-NETs were positive for both synaptophysin and chromogranin. In contrast, our experience showed CD56 was expressed in only 44% (7 of 16) of P-NETs. Pancreatic neuroendocrine tumors were frequently negative for both CK7 and CK20. Other investigators (90) have reported approximately 10% of P-NETs were positive for CK7 or CK20. CK19 positivity in P-NETs may be associated with a more-aggressive clinical behavior. (91,92)

Several relatively P-NET-specific immunomarkers have been reported, including progesterone receptor (PR), paired box gene 8 (PAX8), pancreatic and duodenal homeobox 1 (PDX1) and islet-1. (90,93-100) Progesterone receptor has been reported in 55% to 58.5% of P-NETs, (93) which was similar to our finding of PR immunoreactivity in 56% (9 of 16) of PNETs. Progesterone receptor immunoreactivity showed a significant correlation with the absence of metastasis and lack of invasion into the adjacent organs and large vessels. (93,94) Progesterone receptor expression in other neuroendocrine tumors (NETs) was very rare, with the exception of rare cases reported in lung carcinoid and duodenal NETs. (93,94) Estrogen receptor expression in P-NETs was generally absent.

PAX8 is a member of the paired box (PAX) family of transcription factors involved in the development of thyroid follicular cells and the expression of thyroid-specific genes and, together with PAX2, is involved in the regulation of the organogenesis of the kidney and the Mullerian system. PAX8 has been demonstrated to be a highly sensitive and relatively specific marker for thyroid follicular cell tumors, RCCs, ovarian carcinomas, endometrial ADCs, and thymic tumors. Immunoreactivity to PAX8 was seen in 50% to 74% of P-NETs. (95-97) One study (95) showed PAX8 expression was seen in a significant percentage of duodenal and rectal NETs and 27% of SPTs of the pancreas. The immunoreactivity to PAX8 has been proven a consistent staining artifact by the cross-reaction between the anti-PAX8 antibody and PAX6 antigen. (98)

The human insulin gene enhancer-binding protein islet-1 is a transcription factor involved in the differentiation of pancreatic endocrine cells. Graham et al (99) showed islet-1 expression in 90% of P-NETs, 89% of duodenal NETs, 100% of rectal NETS, 38% of colonic NETs, and a small percentage of NETs from other organs. Koo and coworkers (100) reported that islet-1 was positive in 27 of 33 (82%) and in 19 of 28 (68%) of primary and metastatic P-NETs, respectively. Additionally, Agaimy et al (101) demonstrated that islet-1 expression was seen in nearly all extrapancreatic, poorly differentiated neuroendocrine carcinomas, such as pulmonary small cell carcinoma, Merkel cell carcinoma, medullary thyroid carcinoma, and adrenal neuroblastoma, whereas pancreatic poorly differentiated neuroendocrine carcinomas usually lacked islet-1 expression. These findings argue against the diagnostic value of using islet-1 to identify a pancreatic origin when dealing with a poorly differentiated neuroendocrine carcinoma.

PDX1 is a Hox-type transcription factor that regulates both exocrine and endocrine pancreatic differentiation and maintains [beta]-cell function. Chan et al (90) reported expression of PDX1 in 72% (18 of 25) of P-NETs, 10% (3 of 29) of pulmonary NETs, and 4% (1 of 26) of gastrointestinal NETs. The expression of PDX1 was also seen in 5 of 5 metastatic PNETs (100%) in the liver and 2 of 2 metastatic duodenal NETs (100%) in the liver. (90) They suggested PDX1 was a highly sensitive and specific marker for P-NETs. (90) Another study demonstrated that PDX1 expression was frequently associated with the type of hormone secreted by a NET, regardless of whether it was of pancreatic or duodenal origin. (102) Most insulin- and gastrin-secreted NETs were positive for PDX1, whereas glucagon-, somatostatin-, or serotonin-positive NETs usually lacked PDX1 expression. (102) Based on those data, PDX1 appears to be a specific marker for identifying insulin-positive or gastrin-positive NETs that originate from either the pancreas or duodenum.

An example of a pancreatic neuroendocrine neoplasm with positive staining for PR, PAX8, and islet-1 is shown in Figure 3, A through D. The useful immunomarkers for PNETs, including Geisinger Medical Center (Danville, Pennsylvania) data, are summarized in Table 5. A panel of immunomarkers that includes CK7, CK20, thyroid transcription factor 1 (TTF1), CDX2, cadherin-17 (CDH17), special AT-rich sequence-binding protein 2 (SATB2), PR, PDX1, and PAX8 is useful in differentiating a P-NET from a NET of other organs, which was described in the Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain Origin article by Lin and Liu. (126)

Solid Pseudopapillary Tumor of the Pancreas

Solid pseudopapillary tumor is rare and only accounts for 1% to 2% of pancreatic exocrine neoplasms and 5% of cystic neoplasms. (1,2) It is defined as a low-grade malignant neoplasm that occurs predominately in adolescent girls or young women. Numerous immunomarkers for SPT have been reported in the literature, as listed in Table 6. (103-110) [beta]-catenin, E-cadherin, CD10, vimentin, and chromogranin are the most effective IHC panel for confirming the diagnosis of SPT. (103-110) More than 90% of SPTs showed both nuclear and cytoplasmic staining for [beta]-catenin and loss of E-cadherin expression. (104,105) Chromogranin was consistently negative in SPT, which was a useful feature in differentiating it from a P-NET. Both CD10 and vimentin were positive in nearly all reported SPTs.

Approximately 50% of SPTs expressed CD117 (c-Kit); however, CD117 expression was not associated with underlying mutations of the KIT gene. (111) A representative SPT case is shown in Figure 4, A through F.


Pancreatoblastoma is a very rare pancreatic neoplasm in adults, accounting for less than 1% of all pancreatic tumors. However, it is the most common neoplasm in childhood, accounting for about 25% of all pancreatic neoplasms seen before age 10 years. (1,112) Most PBs consist of both acinar and squamous components; some may also contain endocrine and ductal components. (1,112) The immunostaining results are largely dependent on the components in the tumor. Nuclear staining of [beta]-catenin has been reported in a significant percentage of cases, which is similar to the findings in SPTs and ACCs. (85,113) The "squamous component" usually lacks the typical squamous immunophenotype, that is, being positive for CK5/6, CK14, and CK17. Instead, that component is usually positive for epithelial membrane antigen, CK8, CK18, and CK19 but negative for CK7. Loss of DPC4 expression has been reported in up to 22% of cases, and p53 expression was usually not seen. (85) [alpha]-Fetoprotein may be positive in some cases, which is in keeping with the primitive nature of this neoplasm. The useful immunomarkers for PB are summarized in Table 7.


Serous cystadenoma is an uncommon neoplasm of the pancreas, accounting for 1% to 2% of all pancreatic neoplasms. (1,2) It more often occurs in a middle-aged or older woman in the body or tail of the pancreas. (1,2) A malignant counterpart, serous cystadenocarcinoma, has been reported, which has a similar IHC profile as a benign SCA. Periodic acid-Schiff for glycogen is usually positive, and mucicarmine for mucin is usually negative. Both pVHL and MUC6 tend to show diffuse and strong cytoplasmic and membranous staining (64); in contrast, in our experience both neuron-specific enolase (NSE) and inhibin-[alpha] more frequently show focal and weak staining. The reports of the expression of neuroendocrine markers, such as CD56, synaptophysin, and chromogranin A, were inconsistent. (114,115) Our experience and studies by others showed that SCA was usually negative for those 3 markers. However, a recent study (115) of 12 cases of SCA demonstrated that CD56, synaptophysin, and chromogranin A were expressed in 75%, 92%, and 0% of the cases, respectively. Those data suggested that only chromogranin A was a useful marker in distinguishing SCA from P-NET. Many cases may be positive for EPCAM and CA19-9, which are also positive in a high percentage of pancreatic mucin-producing neoplasms and DADCs. The useful immunomarkers from the literature and from our data are summarized in Table 8. An example of a solid variant of SCA with diffuse and strong positivity for pVHL, MUC6, and inhibin-[alpha] is shown in Figure 5, A through D.


Mucinous cystic neoplasms of the pancreas are relatively uncommon neoplasms, accounting for approximately 8% of surgically resected pancreatic cystic lesions. (1,2) They occur almost exclusively in women, with a female to male ratio of 20:1. (1,2) Mucinous cystic neoplasms consist of 2 components, an epithelial lining, and a subepithelial ovarian-type stroma. The ovarian-type stroma is the key feature to differentiate MCN from IPMN, (1,2) which is usually positive for PR, ER, smooth muscle actin, CD10, and inhibin-[alpha]. (116) Expression of different types of mucin, such as MUC5AC, is not very useful in differentiating an MCN from an IPMN. MUC2 is frequently expressed in goblet cells of MCN. MUC1 tends to be negative in a noninvasive MCN. DPC4/SMAD4 expression is retained. Mucinous cystic neoplasms with an invasive component may show a loss of DPC4/SMAD4 expression and express MUC1. (1) Loss of expression of pVHL and overexpression of S100P were the frequent findings in MCNs, regardless of the grade of epithelial dysplasia. (64) The review of the literature and our Geisinger Medical Center data are summarized in Table 9.


Intraductal papillary mucinous neoplasms are relatively common cystic neoplasms of the pancreas, accounting for approximately 20% of all cystic pancreatic lesions. (1,2) Intestinal-type IPMN is usually positive for MUC2, CDX2, and CK20. Gastric foveolar-type IPMN is usually positive for MUC5AC and negative for both MUC1 and MUC2. Pancreatobiliary-type IPMN is usually positive for MUC1 and MUC5AC and negative for MUC2 and CDX2. Oncocytic type IPMN is usually positive for MUC5AC and MUC6.

Studies showed S100P expression and loss of expression of pVHL in all types of IPMN, regardless of the grade of epithelial dysplasia. (64,65) Expression of DPC4/SMAD4 was present in all tested cases in our study. Expression of MUC1, loss of expression of DPC4/SMAD4, and overexpression of p53 in IPMNs were frequently associated with invasive carcinoma. (117) MUC6 tended to be expressed in the basal layer of epithelial cells; the papillary structures projecting into the cystic space were frequently negative for MUC6. Maspin expression increased with increasing grade of dysplasia in noninvasive lesions from intraductal papillary mucinous adenomas to intraductal papillary mucinous borderline neoplasm to noninvasive intraductal papillary mucinous carcinoma but decreased significantly in invasive intraductal papillary mucinous carcinomas. (118) The literature and our Geisinger Medical Center data are summarized in Table 10.


Metastatic neoplasms of the pancreas are rare, accounting for approximately 2% of all pancreatic malignancies. (1,2) The most common malignancies metastasizing to the pancreas are RCC, melanoma, non-small cell carcinoma of the lung, colorectal ADC, and breast carcinoma. (119) The common metastases to the pancreas and useful immunomarkers for identifying them are summarized in Table 11. For a detailed discussion of how to work up a tumor of uncertain origin, please refer to the review article Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain Origin by Lin and Liu. (126)

Clear cell RCC is the most common metastasis; it is usually positive for PAX8, pVHL, renal cell carcinoma marker, CD10, and vimentin and is negative for CK7 and CK20. Pulmonary ADC is another frequent metastasis. Approximately 75% of cases are positive for TTF1 and napsin A. Both TTF1 and napsin A are negative in pancreatic DADCs; however, mucinous ADCs of the lung are frequently positive for CDX2 and CK20 and negative for TTF1 and napsin A.

S100 is a highly sensitive (98%), but not specific, marker for screening of melanoma. If a desmoplastic melanoma is suspected, sex-determining region Y box 10 (SOX10) should also be included. Other markers, including melanoma-associated antigen recognized by T cells 1 (MART1), human melanoma black 45 (HMB45) and microphthalmia-associated transcription factor (MiTF), are helpful. Caution should be taken if the sample is fixed in alcohol because the S100 antigen is not preserved well after alcohol fixation; therefore, a false-negative result may occur.

Some metastatic small cell carcinomas of the lung can be negative for both synaptophysin and chromogranin and even for broad-spectrum cytokeratin, but they are very infrequently negative for CD56. The MIB-1 (Ki-67) proliferative index tends to be very high (>50%). It would be extremely unusual to have a small cell carcinoma with only a moderately increased MIB-1 (Ki-67) proliferative index.

Nearly 100% of metastatic colonic ADCs are positive for SATB2, CDH17, and CDX2; however, medullary carcinoma of the large intestine frequently demonstrates loss of expression of both CDX2 and CK20. In this instance, the tumor cells would likely demonstrate loss of expression of either MLH1/PMS2 or mutS homolog 2 (MSH2)/MSH6, and are frequently positive for SATB2, CDH17, trefoil factor 3 (TFF3), MUC4, and calretinin. (120)

Entirely tissue-specific markers for the distinction between pancreatic ADC and upper gastrointestinal ADC are not available now. However, loss of DPC4/SMAD4 expression, negative CDH17 expression, and expression of CK17 are suggestive of a pancreatic primary.


Following an extensive study and review of literature, we believe the 4-marker panel of pVHL, maspin, IMP3, and S100P is the most sensitive and specific diagnostic panel to differentiate ADC of the gallbladder and extrahepatic bile ducts from reactive gallbladder/bile duct mucosa (58-60); findings are summarized in Table 12. Other immunomarkers from recent publications are briefly reviewed here. Glucose transporter 1 (GLUT1) has been reported121 to be expressed in 51.8% (N = 115) of ADCs of the gallbladder and not expressed in normal/benign gallbladder mucosa. Riener and coworkers (122) studied the expression of P-cadherin, CD24, and p53 in 39 cases of gallbladder ADC and demonstrated their expression in 64%, 42%, and 45% of cases, respectively; in contrast, all 52 cases of normal/ reactive gallbladder mucosa were negative for all 3 proteins. Tamura et al (123) reported expression of regenerating islet-derived family, member 4 (REG4) was seen in 56% of gallbladder carcinomas (N = 34) and was negative in all normal/reactive cases (N = 28). Li et al (124) reported the expression frequencies for CDX2 and hepatocyte paraffin-1 were 45.4% and 41.7% in gallbladder carcinomas (N = 108) and 14.3% and 5.7% in chronic cholecystitis (N = 35), respectively; p16 was shown to be expressed in 45% of high-grade dysplasias and in 27.6% of gallbladder ADCs (N = 20) but was negative in 20 normal/reactive cases. (125)

In contrast to ADCs of the pancreas, gallbladder, and extrahepatic bile ducts, ICC has a unique IHC profile, as summarized in Table 13, in which, 71% of ICCs were positive for pVHL, and the expression of S100P, MUC5AC, and CK17 was seen in only 27%, 12%, and 12% of cases, respectively. (61)

In summary, application of IHC in the diagnosis and classification of a pancreatic solid or cystic tumor has become a useful ancillary study and plays a crucial role in reaching a definitive diagnosis. An accurate diagnosis of a pancreatic tumor is essential in understanding tumor pathobiology, in making an appropriate therapeutic decision, and in predicting a prognostic outcome. This review article (1) recommends a simple working algorithm for workup of a solid or cystic pancreatic tumor, (2) discusses the emerging biomarkers for common pancreatic tumors with a focus on their application and pitfalls, and (3) identifies the most effective IHC panels for solving frequently encountered diagnostic challenges and minimizing overuse or underuse of the currently available and rapidly growing list of biomarkers. With advances in molecular methodologies, additional tissue-specific biomarkers for ADCs of the pancreas, gallbladder, and extrahepatic and intrahepatic bile ducts will be discovered in the future.

Please Note: Illustration(s) are not available due to copyright restrictions.


(1.) Hruban RH, Boffetta P, Hiraoka N, et al. Ductal adenocarcinoma of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, and Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010:279-334. World Health Organization Classification of Tumours; vol 3.

(2.) Hruban RH, Pitman MB, Klimstra DS. Tumors of the Pancreas. Washington, DC: American Registry of Pathology and Armed Forces Institute of Pathology; 2007:103-164. AFIP Atlas of Tumor Pathology; 4th series, fascicle 6.

(3.) Lin F, Wang HL. Pancreas and ampulla. In: Lin F, Prichard JW, Liu H, Wilkerson M, Schuerch C, eds. Handbook of Practical Immunohistochemistry: Frequently Asked Questions. New York, NY: Springer; 2011:367-388.

(4.) Chu PG, Weiss LM. Tumors of the digestive system. In: Modern Immunohistochemistry. New York, NY: Cambridge University Press; 2009:188-269.

(5.) Basturk O, Farris, AB III, Adsay NV. Immunohistology of the pancreas, biliary tract, and liver. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2010:541-592.

(6.) Geller SA, Dhall D, Alsabeh R. Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med. 2008;132(3):490-499.

(7.) Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of Vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001;115(5):695-702.

(8.) Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol. 2005;29(3):381-389.

(9.) Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13(9):962-972.

(10.) Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarci noma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005; 29(3):359-367.

(11.) Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33(12):1175-1181.

(12.) Bhardwaj A, Marsh WL Jr, Nash JW, Barbacioru CC, Jones S, Frankel WL. Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch Pathol Lab Med. 2007;131(4):556-562.

(13.) Coppola D, Lu L, Fruehauf JP, et al. Analysis of p53, p21WAF1, and TGFb1 in human ductal adenocarcinoma of the pancreas: TGF-b1 protein expression predicts longer survival. Am J Clin Pathol. 1998;110(1):16-23.

(14.) Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol. 1999;30(2):123-129.

(15.) DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol. 1994;101(6):684-688.

(16.) Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27(3):303-310.

(17.) Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF Jr. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16(9): 913-919.

(18.) De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med. 2005;129(9):1100-1105.

(19.) Ordonez NG. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am J Clin Pathol. 2013;139(5):611-619.

(20.) Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29(2):188-195.

(21.) Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 201;42(3):303-314.

(22.) Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Hartmann A, Riener MO. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2011; 35(6):873-877.

(23.) Zhao H, Mandich D, Cartun RW, Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 2007;35(11):700-704.

(24.) Ohike N, Maass N, Mundhenke C, et al. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett. 2003;199(2):193-200.

(25.) Cao D, Zhang Q, Wu LS, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol. 2007;20(5):570-578.

(26.) Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31(2):119-125.

(27.) Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61(11):43204324.

(28.) McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol. 2003;11(3):238-243.

(29.) Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am I Surg Pathol. 2003;27(11):1418-1428.

(30.) Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124(6):838-845.

(31.) Frierson HFJr, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605-609.

(32.) Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35(3):357-366.

(33.) Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol. 2007;35(3):143-147.

(34.) Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol. 2005;18(6):752-761.

(35.) Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008;32(2):188-196.

(36.) Sato N, Fukushima N, Maitra A, et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol. 2004;164(3):903-914.

(37.) Tsukahara M, Nagai H, Kamiakito T, et al. Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int. 2005;55(2):63-69.

(38.) Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186.

(39.) Chhieng DC, Benson E, Eltoum I, et al. MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer. 2003; 99(6):365-371.

(40.) Giorgadze TA, Peterman H, Baloch ZW, et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation. Cancer. 2006;108(3):186197.

(41.) Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001;25(7):942-948.

(42.) Ohuchida K, Mizumoto K, Egami T, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res. 2006; 12(18):5411-541 6.

(43.) Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166(1):81-92.

(44.) Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100Pas novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23(8):1531-1538.

(45.) Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129(1):81-88.

(46.) Lin F, Shi J, Liu H, et al. Diagnostic utility of S100Pand von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32(1):78-91.

(47.) Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129(4):592-605.

(48.) Liu H, Shi J, Anandan V, et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136(6):601-609.

(49.) Yamaguchi H, Inoue T, Eguchi T, et al. Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol. 2007;20(5):552-561.

(50.) Lu SH, Yuan RH, Chen YL, Hsu HC, Jeng YM. Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system. Histopathology. 2013;63(5):640-648.

(51.) Bausch D, Thomas S, Mino-Kenudson M. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res. 2011;17(2):302-309.

(52.) Chung YT, Matkowskyj KA, Li H, et al. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Mod Pathol. 2012;25(5):758-766.

(53.) Dhall D, Suriawinata AA, Tang LH, Shia J, Klimstra DS. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Hum Pathol. 2010;41(5):643-652.

(54.) Detlefsen S, Brasen JH, Zamboni G, Capelli P, Kloppel G. Deposition of complement C3c, immunoglobulin (Ig)G4 and IgG at the basement membrane of pancreatic ducts and acini in autoimmune pancreatitis. Histopathology. 2010; 57(6):825-835.

(55.) Deshpande V, Gupta R, Sainani N, et al. Subclassification of autoimmune pancreatitis: a histologic classification with clinical significance. Am J Surg Pathol. 2011;35(1):26-35.

(56.) Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673-682.

(57.) Sudarshan S, Linehan WM. Genetic basis of cancer of the kidney. Semin Oncol. 2006;33(5):544-551.

(58.) Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41(9):1210-1219.

(59.) Schmidt MT, Himmelfarb EA, Shafi H, Lin F, Xu H, Wang HL. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy. Appl Immunohistochem Mol Morphol. 2012;20(5):478-487.

(60.) Shi J, Liu H, Wang HL, Prichard JW, Lin F. Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder. Hum Pathol. 2013;44(4):503-511.

(61.) Lok T, Chen L, Lin F, Wang HL. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol. 2014;45(2):394-400.

(62.) Aishima S, Fujita N, Mano Y, et al. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol. 2011;35(4):590-598.

(63.) Tsai JH, Huang WC, Kuo KT, Yuan RH, Chen YL, Jeng YM. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Histopathology. 2012;61(6): 1106-1116.

(64.) Liu H, Shi J, Wang HL, et al. Expression of von Hippel-Lindau gene product (pVHL) and S100P in cystic neoplasms of the pancreas--with an implication for their roles in tumorigenesis. Ann Clin Lab Sci. 2012;42(2):109-117.

(65.) Nakata K, Nagai E, Ohuchida K, et al. S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol. 2010;41(6):824-831.

(66.) Maesawa C, Ogasawara S, Yashima-Abo A, et al. Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis. J Clin Pathol. 2006;59(3):328-330.

(67.) Kim J, Jang KT, Kim KH, et al. Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer. Tumour Biol. 2010;31(5):471-476.

(68.) Hoshi H, Sawada T, Uchida M, et al. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int J Oncol. 2011; 38(3):619-627.

(69.) Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007; 14(3):243-254.

(70.) Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003; 16(5):403-410.

(71.) Luttges J, Galehdari H, Brocker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol. 2001;158(5):1677-1683.

(72.) Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC, and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep. 2009;22(3): 649-657.

(73.) Boonla C, Sripa B, Thuwajit P, et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol. 2005;11(32):4939-4946.

(74.) Mall AS, Tyler MG, Ho SB, et al. The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract. 2010;206(12):805-809.

(75.) Guedj N, Zhan Q, Perigny M, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009; 51(1):93-101.

(76.) Xiong L, Yang Z, Yang L, Liu J, Miao X. Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder. J Surg Oncol. 2012;105(1):97-103.

(77.) Guedj N, Zhan Q, Perigny M, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009; 51(1):93-101.

(78.) Aishima S, Kuroda Y, Nishihara Y, et al. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour. Histopathology. 2006;49(1):35-44.

(79.) Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K. Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol. 2007; 128(2):255-259.

(80.) Yang HS, Tamayo R, Almonte M, et al. Clinical significance of MUC1, MUC2, and CK17 expression patterns for diagnosis of pancreatobiliary carcinoma. Biotech Histochem. 2012;87(2):126-132.

(81.) Adsay NV, Pierson C, Sarkar F, et al. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001;25(1):26-42.

(82.) Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 2000;156(5):1641-1651.

(83.) Banville N, Geraghty R, Fox E, et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol. 2006;37(11):1498-1502.

(84.) Nakata B, Wang YQ, Yashiro M, et al. Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients. Oncol Rep. 2003;10(4):997-1000.

(85.) Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/b-catenin pathway and chromosome 11p. Am J Pathol. 2001;159(5):1619-1627.

(86.) Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/b-catenin pathway. Am J Pathol. 2002;160(3):953-962.

(87.) Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. Pathol Int. 2013;63(3):176-182.

(88.) La Rosa S, Adsay V, Albarello L, et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol. 2012;36(12):17821795.

(89.) Mounajjed T, Zhang L, Wu TT. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol. 2013;44(4):542-550.

(90.) Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol. 2012 ;36(5):737-743.

(91.) Ali A, Serra S, Asa SL, Chetty R. The predictive value of CK19 and CD99 in pancreatic endocrine tumors. Am J Surg Pathol. 2006;30(12):1588-1594.

(92.) Zhang L, Lohse CM, Dao LN, Smyrk TC. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. Hum Pathol. 201;42(3):324-331.

(93.) Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors: an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70(9):2268-2277.

(94.) Arnason T, Sapp HL, Barnes PJ, Drewniak M, Abdolell M, Rayson D. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology. 2011;93(4):249-528.

(95.) Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24(3):412-424.

(96.) Tacha D, Qi W, Zhou D, Bremer R, Cheng L. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin. Appl Immunohistochem Mol Morphol. 2013;21(1):59-63.

(97.) Lin F, Shi J, Wilkerson M, Liu H. SALL4 and PAX8 expression in carcinomas from various organs [USCAP abstract 956]. Mod Pathol. 2013;26(S2): 230A.

(98.) Lorenzo PI, Jimenez Moreno CM, Delgado I, et al. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol. 2011;136(5):595-607.

(99.) Graham RP, Shrestha B, Caron BL, et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol. 2013;37(3):399-405.

(100.) Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D. Value of islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25(6):893-901.

(101.) Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, et al. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol. 2013;26(7):995-1003.

(102.) Hermann G, Konukiewitz B, Schmitt A, Perren A, Kloppel G. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch. 2011;459(2):147-154.

(103.) Notohara K, Hamazaki S, Tsukayama C, et al. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol. 2000;24(10):1361-1371.

(104.) Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor b-catenin mutations. Am J Pathol. 2002;160(4):1361-1369.

(105.) Tanaka Y, Kato K, Notohara K, et al. Frequent [beta]-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 2001;61(23):8401-8404.

(106.) Audard V, Cavard C, Richa H, et al. Impaired E-cadherin expression and glutamine synthetase overexpression in solid pseudopapillary neoplasm of the pancreas. Pancreas. 2008;36(1):80-83.

(107.) Chetty R, Serra S. Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas: an immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology. 2008;52(3):325-330.

(108.) El-Bahrawy MA, Rowan A, Horncastle D, et al. E-cadherin/catenin complex status in solid pseudopapillary tumor of the pancreas. Am J Surg Pathol. 2008;32(1):1-7.

(109.) Comper F, Antonello D, Beghelli S, et al. Expression pattern of claudins 5 and 7 distinguishes solid-pseudopapillary from pancreatoblastoma, acinar cell and endocrine tumors of the pancreas. Am J Surg Pathol. 2009;33(5):768-774.

(110.) Guo Y, Yuan F, Deng H, Wang HF, Jin XL, Xiao JC. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas. Am J Surg Pathol. 2011;35(6):799806.

(111.) Cao D, Antonescu C, Wong G, et al. Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations. Mod Pathol. 2006;19(9):1157-1163.

(112.) Klimstra DS, Wenig BM, Adair CF, Heffess CS. Pancreatoblastoma: a clinicopathologic study and review of the literature. Am J Surg Pathol. 1995; 19(12):1371-1389.

(113.) Tanaka Y, Kato K, Notohara K, et al. Significance of aberrant (cytoplasmic/ nuclear) expression of b-catenin in pancreatoblastoma. J Pathol. 2003;199(2): 185-190.

(114.) Kosmahl M, Wagner J, Peters K, Sipos B, Kloppel G. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol. 2004;28(3):339-346.

(115.) Kanehira K, Khoury T. Neuroendocrine markers expression in pancreatic serous cystadenoma. Appl Immunohistochem Mol Morphol. 2011;19(2):141-146.

(116.) Handra-Luca A, Flejou JF, Rufat P, et al. Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology. 2006;48(7):813-821.

(117.) Ueda M, Miura Y, Kunihiro O, et al. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology. 2005;52(62):398-403.

(118.) Kashima K, Ohike N, Mukai S, Sato M, Takahashi M, Morohoshi T. Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary Pancreat Dis Int. 2008;7(1):86-90.

(119.) Olson MT, Wakely PE Jr, Ali SZ. Metastases to the pancreas diagnosed by fine-needle aspiration. Acta Cytol. 2013;57(5):473-480.

(120.) Lin F, Shi J, Zhu S, et al. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine [published online ahead of print January 17, 2014]. Arch Pathol Lab Med. doi:10.5858/arpa. 2013-0452-OA.

(121.) Legan M, Tevzic S, Tolar A, Luzar B, Marolt VF. Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder. Pathol Oncol Res. 2011;17(1):61-66.

(122.) Riener MO, Vogetseder A, Pestalozzi BC, et al. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Hum Pathol. 2010;41(11):1558-1565.

(123.) Tamura H, Ohtsuka M, Washiro M, et al. Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol. 2009;40(12): 1686-1692.

(124.) Li QL, Yang ZL, Liu JQ, Miao XY. Expression of CDX2 and hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic type and clinical outcome. Pathol Oncol Res. 2011;17(3):561-568.

(125.) Choi HJ, Yun SS, Kim HJ, Choi JH. Expression of p16 protein in gallbladder carcinoma and its precancerous conditions. Hepatogastroenterology. 2010;57(97):18-21.

(126.) Lin F, Liu H. Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain Origin. Arch Pathol Med. 2014;138(12):1583-1610.

* References 24, 25, 44, 48, 60, 61, 66, 67.

Fan Lin, MD, PhD; Zongming Eric Chen, MD, PhD; Hanlin L. Wang, MD, PhD

Accepted for publication March 25, 2014.

From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania (Drs Lin and Chen);and the Department of Pathology, University of California, Los Angeles (Dr Wang).

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Fan Lin, MD, PhD, Department of Laboratory Medicine, MC 01-31, Geisinger Medical Center, 100 N Academy Ave, Danville, PA 17822 (e-mail:

Caption: Figure 1. Summary of the immunohistochemical profile for each pancreatic neoplasm. Abbreviations: ACC, acinar cell carcinoma; ADC, adenocarcinoma; BCL, B cell/CLL lymphoma; CA, carcinoma; CD, cluster of differentiation; CDX2, caudal type homeobox 2; CK, cytokeratin; CLL, chronic lymphocytic leukemia; DPC4, SMAD family member 4; ER, estrogen receptor; IMP3, insulin-like growth factor II messenger RNA binding protein-3; IPMN, intraductal papillary mucinous neoplasm; maspin, mammary serine protease inhibitor; MCN, mucinous cystic neoplasm; MSI, microsatellite instability; MUC, mucin; N, nuclear; NSE, neuron-specific enolase; PAX8, paired box 8; PB, pancreatoblastoma; PDX1, pancreatic and duodenal homeobox 1; P-NET, pancreatic neuroendocrine tumor; pVHL, von Hippel-Lindau tumor suppressor; PR, progesterone receptor; S100P, placental S100; SCA, serous cystadenoma; SPT, solid pseudopapillary tumor.

Caption: Figure 2. A through H, A representative case of pancreatic ductal adenocarcinoma on hematoxylin-eosin-stained section (A), and loss of expression of von Hippel-Lindau tumor suppressor (pVHL) (B), positive for mammary serine protease inhibitor (maspin) (C), positive for maspin and negative for pVHL (double staining, brown-maspin and red-pVHL; D), positive for placental S100 (E), insulin-like growth factor II messenger RNA binding protein-3 (F), mucin 5AC (G), and loss of SMAD family member 4 (H) (original magnifications X200 [A, D, and E], X400 [B and C and F through H]).

Caption: Figure 3. A through D, A pancreatic neuroendocrine neoplasm on hematoxylin-eosin-stained section (A), and positive for progesterone receptor (B), paired box gene 8 (C), and islet-1 (D) (original magnification X400 [A through D]).

Caption: Figure 4. A through E, A representative case of solid-pseudopapillary tumor on hematoxylin-eosin-stained section (A), and positive for p-catenin (B), cluster of differentiation 10 (C), vimentin (D), progesterone receptor (E), and loss of E-cadherin expression (F) (original magnification X400 [A through E]).

Caption: Figure 5. A through D, A representative case of serous cystadenoma on hematoxylin-eosin-stained section (A), and positive for von Hippel-Lindau tumor suppressor (B), mucin 6 (C), and inhibin-a (D) (original magnification X200 [A through D]).
Table 1. Summary of Useful Markers in Selected Pancreatic Epithelial

Antibodies       DADC    ACC     P-NET      SPT           PB

CK7               +     - or +   + or -      -          + or -
CK19              +     - or +   - or +      -          + or -
Mesothelin        +       -        -         -          + or -
S100P             +       -        -         -          + or -
Maspin            +       -        -         -          + or -
Glypican 3        -     + or -     -         -            ND
[beta]-catenin    M     M or N     M      N and M   N and C, or M+
E-cadherin        +       +        +         -          - or +
Chromogranin      -       -        +         -          - or +
CD10              -       -        +         +          - or +
IMP3              +       -      + or -      -          - or +
Trypsin           -       +        -         -            +

Abbreviations: +, usually more than 75% of cases are positive; -, less
than 5% of cases are positive;+ or -, usually more than 50% of cases
are positive; -or +, less than 50% of cases are positive;ACC, acinar
cell carcinoma;C, cytoplasmic staining;CD10, cluster of
differentiation 10;CK, cytokeratin;DADC, ductal adenocarcinoma;IMP3,
insulin-like growth factor II messenger RNA binding protein-3;M,
membranous staining; maspin, mammary serine protease inhibitor; N,
nuclear staining;ND, no data;PB, pancreatoblastoma;P-NET, pancreatic
neuroendocrine tumor; S100P, placental S100;SPT, solid pseudopapillary
tumor. Antibody order based on the application of the group of
antibodies to a specific entity.

Table 2. Pancreatic Ductal Adenocarcinoma
(DADC) Versus Chronic Pancreatitis

Antibodies      DADC           Pancreatitis

pVHL             -                  +
Maspin           +                  -
S100P            +            - or C + only
IMP3             +                  -
CK17           + or -           Usually -
MUC5AC         + or -               -
p53            + or -       - or very weakly +
mCEA             +        Usually - or focally +
DPC4/SMAD4   Loss (60%)             +
Mesothelin       +            - or weakly +

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
C, cytoplasmic staining;CK17, cytokeratin 17;DPC4, SMAD family
member 4;IMP3, insulin-like growth factor II messenger RNA binding
protein-3;mCEA, monoclonal carcinoembryonic antigen;MUC5AC, mucin
5AC;pVHL, von Hippel-Lindau tumor suppressor; maspin, mammary
serine protease inhibitor; S100P, placental S100. Antibody order
based on the application of the group of antibodies to a specific

Table 3. Summary of Useful Markers for Acinar Cell Carcinoma (ACC),
Pancreatic Neuroendocrine Tumor (P-NET), Solid Pseudopapillary Tumor
(SPT), and Pancreatoblastoma (PB)

Antibodies              ACC          P-NET    SPT        PB

[beta]-catenin   M or rarely N + C     M     N + C   N + C or M+
E-cadherin               +             +       -       - or +
Chromogranin             -             +       -       - or +
CD10                     -             +       +       - or +
Trypsin                  +             -       -          +
Glypican 3            + or -           -       -         ND
BCL10                    +             -       -         ND

Abbreviations: +, usually more than 75% of cases are positive; /, less
than 5% of cases are positive;+ or /, usually more than 50% of cases
are positive; /or +, less than 50% of cases are positive; BCL10, B
cell CLL/lymphoma 10;C, cytoplasmic staining;CD10, cluster of
differentiation 10; CLL, chronic lymphocytic leukemia; M, membranous
staining;N, nuclear staining;ND, no data. Antibody order based on the
application of the group of antibodies to a specific entity.

Table 4. Immunomarkers for Acinar Cell Carcinoma

Antibodies                    Literature

Trypsin                            +
BCL10                              +
Carboxyl ester lipase              +
Glypican-3                      + or -
[beta]-catenin             M or rarely N + C
pVHL                               -
Mesothelin                         -
S100P                              -
CK7                          - or focal +
Chromogranin            - or rare cell positive
Vimentin                        + or -

Abbreviations: +, usually more than 75% of cases are positive; -, less
than 5% of cases are positive; + or -, usually more than 50% of cases
are positive; - or +, less than 50% of cases are positive; BCL10, B
cell CLL/lymphoma 10;C, cytoplasmic staining;CK7, cytokeratin 7;CLL,
chronic lymphocytic leukemia; M, membranous staining;N, nuclear
staining;pVHL, von Hippel-Lindau tumor suppressor;S100P, placental
S100. Antibody order based on the application of the group of
antibodies to a specific entity.

Table 5. Markers for Pancreatic Neuroendocrine
Tumor (a)

Antibodies              Literature   GML Data, No. (%)

Synaptophysin, n = 16       +            16 (100)
Chromogranin, n = 16        +            16 (100)
CD56, n = 16                +             7 (44)
PR, n = 16                + or -          9 (56)
PAX8, n = 32              + or -          15 (47)
PDX1                        +               ND
Islet-1                     +               ND
b-catenin, n = 16           -              0 (0)
CAM 5.2, n = 16             +            16 (100)
CK7, n = 16               - or +           0 (0)
CK20, n = 16                -              1 (6)
Vimentin, n = 16            -             6 (38)
CDX2, n = 16                V              1 (6)
Insulin, n = 16             V             2 (12)
CK19, n = 16              + or -          4 (25)

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
CD56, cluster of differentiation 56; CDX2, caudal type homeobox2;
CK, cytokeratin;GML, Geisinger Medical Laboratories; ND, no data;
PAX8, paired box gene 8; PDX1, pancreatic and duodenal homeobox
1;PR, progesterone receptor; V, variable. Antibody order based on
the application of the group of antibodies to a specific entity.

(a) Reprinted from 3Lin F, Prichard JW, Liu H, Wilkerson M,
Schuerch C, eds. Handbook of Practical Immunohistochemistry:
Frequently Asked Questions. New York, NY: Springer; 2011, with
permission from Springer Science + Business Media.

Table 6. Markers for Solid-Pseudopapillary
Neoplasm of the Pancreas

Antibodies                       Literature

[beta]-catenin                 N + C positive
E-cadherin                           -
Chromogranin                         -
CD10                                 +
Vimentin                             +
AE1/AE3                        - or focally +
CK7                            - or focally +
Trypsin                              -
[alpha]-1 antitrypsin                +
CD56                                 +
NSE                                + or -
Synaptophysin                      - or +
Claudin 5                           M +
Claudin 7                     - or focally C +
Progesterone receptors (PR)        + or -
PAX8                               - or +
Estrogen receptors (ER)              -
CD99                          + (C dot stain)
Galectin 3                           +
CD117 (c-Kit)                      + or -

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
C, cytoplasmic staining;CD, cluster of differentiation;CK,
cytokeratin;M, membra- nous staining;N, nuclear staining;NSE,
neuron-specific enolase;PAX8, paired box gene 8. Antibody order
based on the application of the group of antibodies to a specific

Table 7. Markers for Pancreatoblastoma

Antibodies       Acinar   Endocrine   Ductal

CK7                +          -         +
CK19               +          -         +
CAM 5.2            +          +         +
Trypsin            +          -         -
NSE                -          +         -
Synaptophysin      -          +         -
Chromogranin       -          +         -
CEA                -          -         +
TAG 72 (B72.3)     -          -         +

Abbreviations: +, usually more than 75% of cases are positive;-, less
than 5% of cases are positive;CEA, carcinoembryonic antigen;CK,
cytokeratin;NSE, neuron-specific enolase;TAG72 (B72.3), tumor
-associated glycoprotein 72. Antibody order based on the
application of the group of antibodies to a specific entity.

Table 8. Markers for Serous Cystadenomaa

Antibodies               Literature   GML Data, No. (%)

pVHL, n = 13                 +            13 (100)
MUC6, n = 13               + or -          12 (92)
Inhibin-[alpha], n = 13      +             12 (92)
NSE, n = 13                  +             7 (54)
CK7, n = 13                  +            13 (100)
CK20, n = 13                 -              0 (0)
S100P, n = 13                -              0 (0)
Synaptophysin, n = 13      - or +           0 (0)
Chromogranin, n = 13         -              0 (0)
TAG 72 (B72.3), n = 13       -              0 (0)
CEA, n = 13                  -              0 (0)
CA19-9, n = 13             - or +          4 (31)
EPCAM, n = 13                -             9 (69)
Mucicarmine, n = 13          -              0 (0)

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
CA19-9, cancer antigen 19.9;CEA, carcinoembryonic antigen;CK,
cytokeratin;GML, Geisinger Medical Laboratories;MUC6, mucin 6;NSE,
neuron-specific enolase;pVHL, von Hippel-Lindau tumor
suppressor;S100P, placental S100;TAG72 (B72.3), tumor-associated
glycoprotein 72. Antibody order based on the application of the
group of antibodies to a specific entity.

(a) Reprinted from 3Lin F, Prichard JW, Liu H, Wilkerson M, Schuerch
C, eds. Handbook of Practical Immunohistochemistry: Frequently
Asked Questions. New York, NY: Springer;2011, with permission from
Springer Science + Business Media.

Table 9. Markers for Mucinous Cystic Neoplasm (a)

                                             GML Data,
Antibodies                      Literature    No. (%)

CK7, n = 12                         +        12 (100)
S100P, n = 12                       +         8 (67)
pVHL, n = 12                        -         4 (33)
CD10, n = 12                        +         4 (33)
Estrogen receptor, n = 12           +         3 (25)
Inhibin-[alpha], n = 12           + or -      8 (67)
Progesterone receptor, n = 12     + or -      6 (50)
CK20, n = 12                      - or +      4 (33)
CEA, n = 12                         +        12 (100)
CA19-9, n = 12                      +         11 (92)
CDX2, n = 12                        -         3 (25)
MUC1, n = 12                        -         2 (17)
MUC2, n = 12                      - or +       0 (0)
MUC5AC, n = 12                      +         8 (67)
MUC6, n = 12                        -         6 (50)
DPC4/SMAD4, n = 12                  +        12 (100)

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
CA19-9, cancer antigen;CD, cluster of differentiation;CDX2, caudal
type homeobox 2; CEA, carcinoembryonic antigen;CK, cytokeratin
19-9;DPC4/SMAD4, SMAD family member 4;GML, Geisinger Medical
Laboratories;MUC, mucin;pVHL, von Hippel-Lindau tumor
suppressor;S100P, placental S100. Antibody order based on the
application of the group of antibodies to a specific entity.

(a) Reprinted from 3Lin F, Prichard JW, Liu H, Wilkerson M,
Schuerch C, eds. Handbook of Practical Immunohistochemistry:
Frequently Asked Questions. New York, NY: Springer;2011, with
permission from Springer Science + Business Media.

Table 10. Markers for Intraductal Papillary
Mucinous Neoplasm (a)

                                   GML Data,
Antibodies            Literature   No. (%)

CK7, n = 18               +        18 (100)
S100P, n = 18             +        18 (100)
pVHL, n = 18              -         0 (0)
CK19, n = 16              +        12 (75)
CK20, n = 16            - or +     10 (62)
CDX2, n = 16            + or -      6 (38)
CEA, n = 18               +        18 (100)
CA19-9, n = 16            +        10 (62)
MUC1, n = 18              V         9 (50)
MUC2, n = 18              V         8 (44)
MUC5AC, n = 18            +        18 (100)
MUC6, n = 18              ND       14 (78)
DPC4/SMAD4, n = 18        +        18 (100)

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
ND, no data; V, variable; CK, cytokeratin; S100P, placental S100;
pVHL, von Hippel-Lindau tumor suppressor; CDX2, caudal type
homeobox 2; CEA, carcinoembryonic antigen; CA19-9, cancer antigen
19-9; GML, Gei-singer Medical Laboratories; MUC, mucin; DPC4/SMAD4,
SMAD family member 4. Antibody order based on the application of
the group of antibodies to a specific entity.

(a) Reprinted from 3Lin F, Prichard JW, Liu H, Wilkerson M,
Schuerch C, eds. Handbook of Practical Immunohistochemistry:
Frequently Asked Questions. New York, NY: Springer; 2011, with
permission of Springer Science + Business Media.

Table 11. Metastases in the Pancreas

Markers    PDADC    Kidney   Lung-A   Melanoma

CK7          +        -        +         -
CK20         -        -        -         -
S100         -        -      + or -      +
GATA3        -        -        -         -
ER           -        -        -         -
TTF1         -        -        +         -
Napsin A     -      - or +     +         -
SATB2        -        -        -         -
pVHL         -        +        -         -
PAX8         -        +        -         -
Synap        -        -        -         -
DPC4       - or +     +        +         +
CK17       + or -     -        -         -

Markers    Upper GI   Lung-S   Colon   Breast

CK7           +       + or -     -       +
CK20        + or -      -        +       -
S100          -         -        -     - or +
GATA3         -         -        -       +
ER            -         -        -       +
TTF1          -         +        -       -
Napsin A      -         -        -       -
SATB2       - or +      -        +       -
pVHL          -         -        -       -
PAX8          -         -        -       -
Synap         -         +        -       -
DPC4          +         +        +       +
CK17          -         -        -       -

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; -or +, less than 50% of cases are positive;
CK, cytokeratin; DPC4, SMAD family member 4; ER, estrogen
receptors; GATA3, GATA binding protein 3; GI, gastrointestinal;
lung-A, lung adenocarcinoma; lung-S, lung small cell carcinoma;
PAX8, paired box gene 8; PDADC, pancreatic ductal adenocarcinoma;
pVHL, von Hippel-Lindau tumor suppressor; SATB2, special AT-rich
sequence-binding protein 2; synap, synaptophysin; TTF1, thyroid
transcription factor 1.

Table 12. Gallbladder and Extrahepatic Bile Duct
Adenocarcinoma (ADC) Versus Reactive Condition

         Gallbladder   Extrahepatic    Reactive
Marker       ADC       Bile Duct ADC   Condition

pVHL          -              -             +
Maspin        +             ND          - or +
S100P         +              +             -
IMP3          +              -             -
mCEA          +              +             -

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; - or +, less than 50% of cases
are positive; IMP3, insulin-like growth factor II messenger RNA
binding protein-3; maspin, mammary serine protease inhibitor;mCEA,
mono- clonal carcinoembryonic antigen;ND, no data;pVHL, von
Hippel-Lindau tumor suppressor;S100P, placental S100.

Table 13. Intrahepatic Cholangiocarcinomas (ICCs)
Versus Pancreatic Ductal Adenocarcinomas (DADC)

Marker    Pancreatic DADC    ICC

pVHL             -            +
S100P            +          - or +
CK17          + or -          -
MUC5AC        + or -          -

Abbreviations: +, usually more than 75% of cases are positive; -,
less than 5% of cases are positive; + or -, usually more than 50%
of cases are positive; - or +, less than 50% of cases are positive;
CK17, cytokeratin 17; MUC5AC, mucin 5AC; pVHL, von Hippel-Lindau
tumor suppressor; S100P, placental S100.
COPYRIGHT 2015 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Lin, Fan; Chen, Zongming Eric; Wang, Hanlin L.
Publication:Archives of Pathology & Laboratory Medicine
Date:Jan 1, 2015
Previous Article:Next-Generation Companion Diagnostics: Promises, Challenges, and Solutions.
Next Article:Immunohistochemistry in Dermatopathology.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |